Abstract: Thermal responsive compositions for treating bone diseases are provided. The thermal responsive composition for treating bone diseases includes a bone growth factor and a biodegradable copolymer. The biodegradable copolymer has a structure of Formula (I) or Formula (II): A-B-BOX-B-A??Formula (I) B-A-B-(BOX-B-A-B)n-BOX-B-A-B??Formula (II) wherein, A includes a hydrophilic polyethylene glycol polymer, B includes a hydrophobic polyester polymer, BOX is a bifunctional group monomer of 2, 2?-Bis(2-oxazoline) and used for coupling the blocks A-B or B-A-B, and n is an integer and the same or more than 0.
Type:
Grant
Filed:
June 29, 2011
Date of Patent:
December 24, 2013
Assignee:
Industrial Technology Research Institute
Abstract: This disclosure provides modified antimicrobial agents, for example modified defensin polypeptides. Compositions including a modified arginine residue, such as an ADP-ribosylated and/or ribosylated alpha defensin polypeptide, are provided. Also provided are methods of modulating an immune response using the modified defensin polypeptides. Methods are provided for modulating an antimicrobial activity and for inhibiting a cytotoxic activity. Also disclosed are methods for treating diseases in a subject that are associated with an immune response, such as inflammatory and pulmonary diseases, using the disclosed modified defensin polypeptides.
Type:
Grant
Filed:
January 5, 2012
Date of Patent:
December 17, 2013
Assignee:
The United States of America as represented by the Secretary of the Department of Health and Human Services
Inventors:
Joel Moss, Rodney L. Levine, Akihiro Wada, Toshiya Hirayama, Gregorino Paone
Abstract: The invention provides a single surgical procedure by using autologous platelet-rich fibrin (PRF) and cartilage fragments to solve problems of contamination during incubation of chondrocytes and transplant rejection in vivo, which has the benefit of a more efficient and shorter recovery time. The invention also provides a device for easily and rapidly cutting cartilage to cartilage fragments so as to reduce contamination of the implant and infection.
Abstract: Isolated human monoclonal antibodies which specifically bind to human EGFR, and related antibody-based compositions and molecules, are disclosed. The human antibodies can be produced by a transfectoma or in a non-human transgenic animal, e.g., a transgenic mouse, capable of producing multiple isotypes of human monoclonal antibodies by undergoing V-D-J recombination and isotype switching. Also disclosed are pharmaceutical compositions comprising the human antibodies, non-human transgenic animals and hybridomas which produce the human antibodies, and therapeutic and diagnostic methods for using the human antibodies.
Type:
Grant
Filed:
May 11, 2009
Date of Patent:
November 19, 2013
Assignee:
Genmab A/S
Inventors:
Jan G. J. van de Winkel, Marcus Antonius van Dijk, Edward Halk, Arnout F. Gerritsen, Jorgen Petersen, Ole Baadsgaard
Abstract: The present invention is directed to prostate specific antigen (PSA) and tumor endothelial marker 8 (TEM8) peptide compositions and methods for treating cancer with the compositions.
Type:
Grant
Filed:
March 6, 2012
Date of Patent:
October 15, 2013
Assignee:
The Board of Trustees of the University of Illinois
Abstract: The present invention relates to a device having osteoinductive and osteoconductive properties in vivo comprising a carrier containing calcium phosphate and an osteoinductive protein, wherein the carrier is homogenously coated with the protein. Moreover, the present invention relates to a method for the production of a device having osteoinductive and osteoconductive properties in vivo. The invention encompasses a pharmaceutical composition comprising the device of the invention or a device which is obtainable by the method of the invention and relates to the use of the device for the preparation of a pharmaceutical composition to be used for bone augmentation, for treating bone defects, for treating degenerative and traumatic disc disease, for treating bone dehiscence or to be used for sinus floor elevation. Finally, the invention relates to a kit comprising the device of the invention or a device which is obtainable by the method of the invention.
Type:
Grant
Filed:
March 27, 2002
Date of Patent:
October 1, 2013
Assignee:
Scil Technology GmbH
Inventors:
Ulrich Kohnert, Sylke Pohling, Klaus Hellerbrand, Peter Happersberger
Abstract: Compositions and methods of treatment for abnormal bone density are disclosed based upon the finding that sclerostin must be bound to glypican in order to inhibit bone deposition. Methods for identifying agents that inhibit the glypican-sclerostin interaction are disclosed for treatment of bone deposition disorders. Diagnostic methods are also disclosed.
Abstract: The present invention relates to an inhibitor protein of the wnt signal path, a DNA encoding such a protein and a process for the preparation of such a protein. In addition, this invention concerns the use of the DNA and the protein as well as antibodies directed against the protein.
Type:
Grant
Filed:
November 20, 2006
Date of Patent:
September 17, 2013
Assignee:
Deutsches Krebsforschungszentrum Stiftung des Offentlichen Rechts
Abstract: Purified genes encoding interleukin-B30 from a mammal, reagents related thereto including purified proteins, specific antibodies, and nucleic acids encoding this molecule are provided. Methods of using said reagents and diagnostic kits are also provided.
Abstract: The present inventors investigated anti-IL-6 receptor antibodies for their effect in suppressing damage to transplanted islets after islet transplantation. As a result, they found that anti-IL-6 receptor antibodies reduced damage to transplanted islets, improved islet survival, and corrected hyperglycemia in recipients. Further, they revealed that administration of the anti-IL-6 receptor antibodies of the present invention suppressed the production of inflammatory cytokines by infiltrating cells after transplantation. Specifically, the present inventors discovered for the first time that damage to transplanted islets after islet transplantation can be suppressed by using anti-IL-6 receptor antibodies according to the present invention.
Abstract: The invention provides a family of antibodies that specifically bind the human cell surface glycosphingolipid GD2. The antibodies comprise modified variable regions, more specially, modified framework regions, which reduce their immunogenicity when administered to a human. The antibodies may be coupled to a therapeutic agent and used in the treatment of cancer.
Type:
Grant
Filed:
April 27, 2010
Date of Patent:
June 25, 2013
Assignee:
Merck Patent GmbH
Inventors:
Stephen D. Gillies, Kin-Ming Lo, Susan Xiuqi Qian
Abstract: The present invention relates to an inhibitor protein of the wnt signal path, a DNA encoding such a protein and a process for the preparation of such a protein. In addition, this invention concerns the use of the DNA and the protein as well as antibodies directed against the protein.
Type:
Grant
Filed:
January 19, 2011
Date of Patent:
June 11, 2013
Assignee:
Deutsches Krebsforschungszentrum Stiftung des Offentlichen Rechts
Abstract: Monoclonal antibodies and hybridomas producing them that interact with osteoprotegerin ligand (OPGL) are provided. Methods of treating osteopenic disorders by administering a pharmaceutically effective amount of antibodies to OPGL are also provided. Methods of detecting the amount of OPGL in a sample using antibodies to OPGL are further provided.
Type:
Grant
Filed:
January 27, 2012
Date of Patent:
June 4, 2013
Assignees:
Amgen Inc., Medarex, Inc.
Inventors:
William J. Boyle, Eugene Medlock, John K. Sullivan, Robin L. Elliott, Frank Martin, Haichun Huang
Abstract: The present invention encompasses IL-18 binding proteins, particularly antibodies that bind human interleukin-18 (hIL-18). Specifically, the invention relates to antibodies that are entirely human antibodies. Preferred antibodies have high affinity for hIL-18 and/or that neutralize hIL-18 activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. Method of making and method of using the antibodies of the invention are also provided. The antibodies, or antibody portions, of the invention are useful for detecting hIL-18 and for inhibiting hIL-18 activity, e.g., in a human subject suffering from a disorder in which hIL-18 activity is detrimental.
Type:
Grant
Filed:
July 26, 2010
Date of Patent:
April 30, 2013
Assignee:
Abbott Laboratories
Inventors:
Tariq Ghayur, Boris Labkovsky, Jeffrey W. Voss, Larry Green, John Babcook, Xiao-chi Jia, James Wieler, Jaspal Singh Kang, Brad Hedberg
Abstract: The present invention provides a biocompatible material in the form of a water insoluble cross-linked gel, which contains a stable complex of TNF-stimulated gene 6 protein (TSG-6) and hyaluronan.
Type:
Grant
Filed:
November 18, 2011
Date of Patent:
April 16, 2013
Assignees:
New York University, Polytechnic Institute of NYU
Inventors:
Hans-Georg Wisniewski, Mary K. Cowman, Philip Band
Abstract: Methods of treating, inhibiting, or ameliorating an autoinflammatory disorder, disease, or condition in a subject in need thereof, comprising administering to a subject in need a therapeutic amount of an interleukin 1 (IL-1) antagonist, wherein the autoinflammatory disorder, disease, or condition is treated, inhibited, or ameliorated. The IL-1 antagonist is a molecule capable of binding and inhibiting IL-1. The therapeutic methods are useful for treating a human adult or child suffering from Neonatal Onset Multisystem Inflammatory Disorder (NOMID/CINCA), Muckle-Wells Syndrome (MWS), Familial Cold Autoinflammatory Syndrome (FCAS), familial mediterranean fever (FMF), tumor necrosis factor receptor-associated periodic fever syndrome (TRAPS), or systemic onset juvenile idiopathic arthritis (Still's Disease).
Type:
Grant
Filed:
September 2, 2011
Date of Patent:
April 9, 2013
Assignee:
Regeneron Pharmaceuticals, Inc.
Inventors:
Scott Mellis, Margaret Karow, George D. Yancopoulos, Joanne Papadopoulos
Abstract: This invention relates to methods employing IL-1?-ligand/IL-1 receptor disrupting compounds (herein referred to as “IL-1beta Compounds”); such as small molecular compounds disrupting IL-1? ligand-IL-1 receptor interaction, IL-1? antibodies or IL-1 receptor antibodies, e.g. IL-1? binding molecules as described herein, e.g. antibodies disclosed herein, e.g. IL-1? binding compounds or IL-1 receptor binding compounds, and/or RNA compounds decreasing either IL-1? ligands or IL-1 receptor protein levels, in the treatment and/or prevention of auto-inflammatory syndromes, e.g. Juvenile rheumatoid arthritis or adult rheumatoid arthritis syndrome and to methods of treating and/or preventing auto-inflammatory syndromes, e.g. Juvenile rheumatoid arthritis or adult rheumatoid arthritis syndrome, in mammals, particularly humans.
Type:
Grant
Filed:
October 27, 2011
Date of Patent:
April 2, 2013
Assignee:
Novartis AG
Inventors:
Phil Lowe, Hermann Gram, Thomas Jung, Timothy Wright, Trevor Mundel
Abstract: EphB3-specific antibodies are provided, along with pharmaceutical compositions containing such antibody, kits containing a pharmaceutical composition, and methods of preventing and treating an EphB3-related disease or disorder.
Abstract: Hybridoma lines that secrete human monoclonal antibodies with high binding specificity and biological activity, particularly neutralizing activity against granulocyte-macrophage colony stimulating factor, and methods of generating the hybridoma lines are provided. Target antigens and epitopes are also provided. The antibodies may be used in therapeutic methods, for example in the treatment of cancer, infectious disease, or autoimmune disease.
Type:
Grant
Filed:
April 16, 2010
Date of Patent:
November 27, 2012
Assignee:
Morphotek, Inc.
Inventors:
Philip M. Sass, Nicholas C. Nicolaides, Luigi Grasso, Jian Li, Qimin Chao, Eric Routhier, Wolfgang Ebel
Abstract: Modulation of iron homeostasis by regulating BMP-6 activity is provided. Methods of using BMP-6 and BMP-6 protein-specific reagents, such as antibodies, for altering serum iron levels in humans are provided. Such antibodies are useful in pharmaceutical compositions for the prevention and treatment of hemochromatosis and anemia of inflammation.